Latest

As pharmaceutical tariffs reshape costs and global supply chains, it’s essential for industry professionals to be informed about their core impacts and underlying mechanisms.

Digital transformation, data integrity protocols, and regionalized supply chains are crucial strategies for optimizing drug development and manufacturing efficiency, as revealed in our exclusive interviews.

Shilpa Biologicals CEO Sridevi Khambhampaty addresses funding pressures, regional supply strategies, and expanding ADC development.

A wide-ranging discussion with RNAnalytics’ Viktoria Enkmann touched upon the technology and equipment necessary for modern nanoparticle analysis, as well as global concerns.

Biologics output improves via planning and automation as digitalization predicts batch outcomes, requiring strong data and worker expertise, KBI Biopharma’s Sigma Mostafa explains.

The second installment of the monthly BioPharma By the Numbers infographic series details the hiring and retention challenges faced by US biopharma.

AI and innovative technology platforms are revolutionizing biopharma R&D and manufacturing, but success requires high data quality and next-gen solutions.

Codexis and Nitto Denko Avecia aim to advance next-gen siRNA production methods for improving scalability of RNA therapeutics.

In the conclusion of a two-part conversation, Viktoria Enkmann of RNAnalytics says she had a hard time understanding the United States’ mRNA decision in August 2025.

Toni Manzano, PhD, discusses his CPHI Europe presentation, stating that AI is essential for managing complex drug and biologics manufacturing.

Biopharma innovators were recognized at CPHI 2025 for advances in drug delivery, continuous bioprocessing, and supply chain capabilities shaping global therapies.

Toni Manzano, PhD, Azion, says AI integration in drug manufacturing necessitates regulatory risk assessment, cloud infrastructure for big data, and strict data integrity compliance.